Somatic mutations predict outcomes of hypomethylating therapy in patients with myelodysplastic syndrome

Although hypomethylating therapy (HMT) is the first line therapy in higher-risk myelodysplastic syndromes (MDS), predicting response to HMT remains an unresolved issue. We aimed to identify mutations associated with response to HMT and survival in MDS. A total of 107 Korean patients with MDS who und...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Oncotarget
Autori principali: Jung, Seung-Hyun, Kim, Yoo-Jin, Yim, Seon-Hee, Kim, Hye-Jung, Kwon, Yong-Rim, Hur, Eun-Hye, Goo, Bon-Kwan, Choi, Yun-Suk, Lee, Sug Hyung, Chung, Yeun-Jun, Lee, Je-Hwan
Natura: Artigo
Lingua:Inglês
Pubblicazione: Impact Journals LLC 2016
Soggetti:
Research Paper
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC5342416/
https://ncbi.nlm.nih.gov/pubmed/27419369
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.10526
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi